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ABSTRACT
Introduction: It is assumed that a direct
relationship exists between the extent of use
of any given antibiotic or antibiotic class and
the degree of susceptibility or resistance on the
part of various bacteria to that antibiotic or
class.
Methods: Pseudomonas aeruginosa susceptibility
rates and utilization of key antipseudomonal
antibiotics in a pediatric hospital, reflected as
grams/1,000 patient days, were studied over a
7-year period.
Results: While the volume of use of a number
of antibiotics changed dramatically over this
time period, susceptibility of Pseudomonas to
these same agents remained relatively stable.
The use of aminoglycosides decreased 14.5%
while that of piperacillin/tazobactam increased
92% over the period of observation while
susceptibility generally varied by \10%.
Conclusion: Contrary to popular belief,
changes in antibiotic utilization patterns do
not always result in changes in susceptibility
thus emphasizing the importance of continual
institutional monitoring of antibiotic use and
susceptibility patterns.
Keywords: Antibiotic utilization; Infectious
disease; Pediatrics; Pseudomonas aeruginosa;
Susceptibility
INTRODUCTION
It is assumed that there is a relationship
between patterns of use of any given antibiotic
or antibiotic class and extent of bacterial
resistance to that antibiotic or class. More
specifically, it is believed that as the use of an
antibiotic increases over time, resistance to that
antibiotic on the part of one or more bacteria
will also increase as would rates of infections
with antibiotic-resistant pathogens. Research in
this area has indeed provided examples of such
relationships although they are not predictably
present [1, 2]. However, when such
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relationships occur, they may well have
implications for proactive stewardship
initiatives and empiric prescribing decisions.
Most, if not all investigations regarding these
potential relationships have been performed in
adult populations with few, if any, studies
focusing in on pediatric drug use/resistance in
pediatric hospitals. The purpose of the present
study was to explore potential relationships
between antipseudomonal antibiotic use and
susceptibility of Pseudomonas aeruginosa, a
common nosocomial pathogen, to these
antibiotics in a pediatric hospital over a 7-year
period.
METHODS
The Medical University of South Carolina
Children’s Hospital is a 186 bed facility
including 50 neonatal specialty beds.
Approximately, 4,700 children between the
ages of 0 and 17 years are cared for annually.
The study was approved by the institution’s
Institutional Review Board. The analysis in this
article is based on existing data, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
Susceptibility data for inpatient-derived P.
aeruginosa isolates collected between January 1,
2006 and December 31, 2012 were retrieved
from hospital microbiology records and
antibiotic use data were retrieved from the
pharmacy database. The antibiotics of interest
were amikacin, cefepime, ciprofloxacin,
gentamicin, meropenem, piperacillin/
tazobactam, and tobramycin and all drug use
was expressed as grams/1,000 patient days. To
have a statistically valid sample of tested
isolates (C30), periods of analysis were divided
into six quarter increments (e.g., January 2006
through June 2007) and we thereby analyzed a
total of six periods within the 7-year time span.
Analysis of potentially significant changes in
either antibiotic use or susceptibility, over time
(period 1 vs. period 4), was performed via paired
t test and Chi-square test, respectively. A trend
analysis (linear regression) of susceptibility over
time was also completed. All statistical analyses
were performed using SPSS v.21 (IBM, Armonk,
NY, USA).
RESULTS
Little change was observed in susceptibility of P.
aeruginosa over the time period of interest with
the biggest change being a 12% difference from
period 1 to period 4 for aztreonam (Table 1).
Conversely, the utilization of most of the
antibiotics increased over time with the
greatest change observed for piperacillin/
tazobactam (92% increase), although overall
antibiotic utilization change was not
statistically significant (Table 1). As a group,
utilization of aminoglycosides decreased (14.5%
decrease for the class). Use of both amikacin and
gentamicin decreased while that of tobramycin
increased. No changes in either susceptibility
proportions or antibiotic utilization were
statistically significant (P[0.05). Trend
analysis of susceptibility over time revealed
poor data fits (as reflected by R2) suggesting no
or weak linearity. As susceptibility of P.
aeruginosa was relatively stable over this time
period, tests of correlation or cause-and-effect
between antibiotic use over time and
susceptibility over time were not pursued.
DISCUSSION
It is generally assumed that increased use of an
antibiotic or antibiotic class within a healthcare
environment will result in rising resistance to
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that drug or class. While not always the case,
some studies have indeed demonstrated that
relationship. By way of example, Plu¨ss-Suard
et al. [3] demonstrated a relationship between
extent of carbapenem resistance in P. aeruginosa
and carbapenem use in a study involving 20
acute care hospitals. Due to such experiences, it
is not unusual to meet the challenge of rising
resistance by decreasing the use of the apparent
offending agent or class and encouraging the
use of alternatives. Again, there is evidence that
this maneuver can be effective. For example,
Martin et al. [4] documented a reduction in
the rate of ceftazidime-resistant Klebsiella
pneumoniae after the removal of ceftazidime
and cefotaxime from the hospital formulary.
However, this strategy is not always successful,
as the relationship between extent of use and
extent of resistance does not always exist [5, 6]
Further, while this strategy may restore
susceptibility to a given drug, it may result in
rising resistance to other drugs that are used in
its stead [7]. In the current analysis, no large
changes in susceptibility were detected despite
some rather large changes in utilization of
individual antibiotics. As examples,
susceptibility rates of P. aeruginosa to
meropenem and piperacillin/tazobactam
remained largely unchanged, despite increases
in use of 70 and 92%, respectively, over the
7-year period of observation. Although no
apparent cause-and-effect relationships seemed
operative, these results might not pertain to
other hospitals especially in light of the
variation in antibiotic use from one pediatric
hospital to the next [8]. The current study must
be viewed in light of being a single-center
experience with a limited number of tested
isolates. All tested isolates were considered and
no attempt was made to distinguish those
causing infection from those that may have
been colonizers. Further, this analysis did not
take into account possible effects from
changing infection control practices during
the period of interest. Lastly, it is also certainly
possible that there could be a significant lag
time between changes in antibiotic use and
changes in resistance rates.
Regardless of these results, it is important
that susceptibility rates be diligently monitored
in the current age of rapidly rising antibiotic
resistance, including in pediatric settings so that
emergent resistant problems can be detected
and addressed [9]. Results from a fairly recent
survey of hospitals caring for pediatric patients
were used to construct a national antibiogram
for the years 2010 and 2011 [10]. With the
exceptions of aztreonam and gentamicin,
reported susceptibility rates for isolates of P.
aeruginosa in that report were similar to those in
our last period of observation. While such
national averages may be helpful in settings
where a local antibiogram cannot be prepared,
local antibiograms are nonetheless the best
resource in guiding empiric prescribing
decisions.
CONCLUSION
In summary, the susceptibility of pediatric
isolates of P. aeruginosa to a number of
antibiotics remained relatively stable over a
7-year period despite major changes in
utilization of several of these drugs. Thus,
large increases in utilization of at least some
antibiotics are not uniformly associated with
subsequent changes in bacterial resistance.
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